185 related articles for article (PubMed ID: 25111376)
1. Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes.
Calastretti A; Gatti G; Quaresmini C; Bevilacqua A
Prostate; 2014 Oct; 74(14):1411-22. PubMed ID: 25111376
[TBL] [Abstract][Full Text] [Related]
2. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase.
Priulla M; Calastretti A; Bruno P; Azzariti A; Paradiso A; Canti G; Nicolin A
Prostate; 2007 May; 67(7):782-9. PubMed ID: 17373720
[TBL] [Abstract][Full Text] [Related]
3. Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis.
Zhang R; Banik NL; Ray SK
Brain Res; 2008 Nov; 1239():216-25. PubMed ID: 18804099
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells.
Ohigashi T; Mizuno R; Nakashima J; Marumo K; Murai M
Prostate; 2005 Jan; 62(1):61-8. PubMed ID: 15389810
[TBL] [Abstract][Full Text] [Related]
5. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression.
Huang H; Cheville JC; Pan Y; Roche PC; Schmidt LJ; Tindall DJ
J Biol Chem; 2001 Oct; 276(42):38830-6. PubMed ID: 11495901
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells.
Isebaert SF; Swinnen JV; McBride WH; Haustermans KM
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):239-47. PubMed ID: 21816290
[TBL] [Abstract][Full Text] [Related]
7. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer.
Rochester MA; Riedemann J; Hellawell GO; Brewster SF; Macaulay VM
Cancer Gene Ther; 2005 Jan; 12(1):90-100. PubMed ID: 15499378
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
[TBL] [Abstract][Full Text] [Related]
9. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
10. PI3K/Akt signaling regulates p27(kip1) expression via Skp2 in PC3 and DU145 prostate cancer cells, but is not a major factor in p27(kip1) regulation in LNCaP and PC346 cells.
van Duijn PW; Trapman J
Prostate; 2006 May; 66(7):749-60. PubMed ID: 16425184
[TBL] [Abstract][Full Text] [Related]
11. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
12. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363.
Lamoureux F; Thomas C; Crafter C; Kumano M; Zhang F; Davies BR; Gleave ME; Zoubeidi A
Clin Cancer Res; 2013 Feb; 19(4):833-44. PubMed ID: 23258740
[TBL] [Abstract][Full Text] [Related]
13. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
14. Alpha-tomatine synergises with paclitaxel to enhance apoptosis of androgen-independent human prostate cancer PC-3 cells in vitro and in vivo.
Lee ST; Wong PF; Hooper JD; Mustafa MR
Phytomedicine; 2013 Nov; 20(14):1297-305. PubMed ID: 23920276
[TBL] [Abstract][Full Text] [Related]
15. Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation.
Flores ML; Castilla C; Gasca J; Medina R; Pérez-Valderrama B; Romero F; Japón MA; Sáez C
Mol Cancer Ther; 2016 Jul; 15(7):1713-25. PubMed ID: 27196755
[TBL] [Abstract][Full Text] [Related]
16. Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.
Ren W; Joshi R; Mathew P
Mol Cancer Res; 2016 Dec; 14(12):1176-1181. PubMed ID: 27590631
[TBL] [Abstract][Full Text] [Related]
17. SRJ23, a new semisynthetic andrographolide derivative: in vitro growth inhibition and mechanisms of cell cycle arrest and apoptosis in prostate cancer cells.
Wong HC; Wong CC; Sagineedu SR; Loke SC; Lajis NH; Stanslas J
Cell Biol Toxicol; 2014 Oct; 30(5):269-88. PubMed ID: 25070834
[TBL] [Abstract][Full Text] [Related]
18. Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells.
Wang C; Huang SB; Yang MC; Lin YT; Chu IH; Shen YN; Chiu YH; Hung SH; Kang L; Hong YR; Chen CH
PLoS One; 2015; 10(3):e0120913. PubMed ID: 25811469
[TBL] [Abstract][Full Text] [Related]
19. IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way.
Zhang X; Wang D; Liu B; Jin X; Wang X; Pan J; Tu W; Shao Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):190. PubMed ID: 32938489
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation.
Rosser CJ; Tanaka M; Pisters LL; Tanaka N; Levy LB; Hoover DC; Grossman HB; McDonnell TJ; Kuban DA; Meyn RE
Cancer Gene Ther; 2004 Apr; 11(4):273-9. PubMed ID: 14765130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
